AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 6, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint...
Hence then, the article about successful extension of nucleic acid aptamer pharmacokinetics in joint research by ajinomoto co inc and ribomic inc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. )
Also on site :
- Amy Schumer Shares Bikini Photos After 50-Pound Weight Loss— ‘Never Knew There Would Be Days Like This’
- Royal Office of Morocco Releases Statement on President Trump's Reaffirmation of U.S. Recognition of Moroccan Sovereignty Over Western Sahara
- 1993 Michael Jackson Song, Once Ranked Among the ‘Worst Music Videos,’ Featured One of Hollywood's Biggest Stars